Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia

What Was Tested

This randomized controlled trial paper looks at Amylin (Islet Amyloid Polypeptide).

The purpose of this study was to examine the effect of continuous sc replacement of amylin and insulin for a 24-h period on glucose homeostasis in adolescents with type 1diabetes.

Who Took Part

By PubMed's age tags, the people studied were teenagers and young adults, both men and women.

In part A, basal and bolus insulin infusion was per prescribed home regimen.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.

In the crossover set-up each of the participants took both Amylin (Islet Amyloid Polypeptide) and the comparison in turn, acting as their own control.

Thirteen adolescents with type 1 diabetes on insulin pump therapy participated in a randomized, controlled, crossover design study comparing continuous sc insulin monotherapy (part A) vs. continuous sc insulin and pramlintide infusion (part B).

Basal and prandial bolus pramlintide were administered simultaneously via another pump.

All boluses were given as a dual wave.

What Was Measured

Topics PubMed links to this paper include Amyloid, Blood Glucose, Diabetes Mellitus, Type 1, Diet, Diabetic, Glucagon, Hormones and Hyperglycemia.

What This Means in Plain Language

The paper is a randomized and crossover study of Amylin (Islet Amyloid Polypeptide).

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.